Rich Pzena’s Latest Portfolio: Top 10 Holdings & Biggest Moves
Rich Pzena Investment Management reported an equity portfolio of about $34.07B in its latest quarter. The top 10 holdings make up 37.56% of assets, with no position above 7%. Largest holdings include MGA (6.54%), HUM (5.13%), BAX (4.09%), CVS (3.57%), DG (3.45%). Biggest changes: CRBG +24.94%, CTSH +30.93%, DG +48.20%, CVS -14.55%.
How this was made
The 30-second read
Why it matters
The only actionable information is the disclosed direction and magnitude of position changes across several large-cap names. It does not provide new company fundamentals, guidance, or regulatory/contract events.
Market read
Traders may use the adds/trims as a sentiment input for CRBG, CTSH, DG, and CVS, but the article does not introduce new fundamental catalysts.
What to watch
The article lacks the underlying filing date, cost basis, and whether changes were driven by price moves versus new capital; without that, the signal is mostly sentiment.
Background
The piece summarizes Rich Pzena’s latest reported equity portfolio, including top holdings and the biggest share changes during the quarter.
Ticker impact
Pzena expanded Corebridge Financial shares by 6,743,933 (+24.94%) to 33.79M, lifting it to a top-ten 2.84% position.
Low to modest positive bias for sentiment; likely limited impact on price absent other catalysts.
This is a disclosed portfolio change, not an earnings, guidance, or corporate event. The magnitude is notable, but the text provides no new company-specific fundamentals.
Pzena increased Cognizant Technology Solutions shares by 6,266,810 (+30.93%) to 26.53M, valuing the stake at about $1.03B.
Slight positive sentiment effect; unlikely to drive sustained repricing alone.
The newest fact is the size of the position change, but there is no accompanying CTSH-specific news (earnings, contract, guidance) in the article.
Pzena aggressively raised Dollar General shares by 3,324,519 (+48.20%) to 10.22M, making it the firm’s fifth-largest holding.
Potential short-term sentiment lift, but fundamental impact is indirect.
The article provides a concrete portfolio action and valuation, but no new DG operational or financial catalyst.
Pzena reduced CVS Health shares by 2,003,517 (-14.55%) while keeping a large 11.77M share position worth about $1.22B.
Mild negative sentiment bias versus the adds, but likely limited price effect.
This is a disclosed allocation change without new CVS-specific news; the net effect is sentiment rather than a fundamental trigger.
Market effects
Adds are concentrated in healthcare (HUM, BAX, CVS, BMY) and consumer/tech (DG, CTSH), consistent with a broad value rotation rather than a single-sector catalyst.
Primarily US large-cap sentiment; no explicit cross-region macro or policy linkage.
No direct global linkage beyond multinational exposure in holdings like MGA and CTSH.
Counterpoint
Portfolio changes by a single value manager may reflect rebalancing or risk management rather than a new view on fundamentals, limiting tradable signal strength.
Key entities
- personRich Pzena
Value investor whose firm’s latest reported portfolio is summarized.
- asset_managerPzena Investment Management
The portfolio manager disclosing holdings and quarter-over-quarter share changes.
